Trial Profile
Phase 2a Randomized, Single-Blind, Placebo-Controlled, 12-week Escalating Dose Study to Assess the Safety, Tolerability and Clinical Activity of 3 Concentrations of Locally Applied MBN-101 to Infected Bone Sites
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2021
Price :
$35
*
At a glance
- Drugs Pravibismane (Primary)
- Indications Bacterial infections
- Focus Adverse reactions
- Sponsors Microbion Corporation
- 27 May 2020 Status changed from active, no longer recruiting to completed, according to a Microbion Corporation media release.
- 09 Aug 2018 Planned End Date changed from 1 Jun 2018 to 31 Dec 2018.
- 09 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Sep 2018.